GE HealthCare (GEHC) Granted FDA Clearance for Portrait VSM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
GE HealthCare (GEHC) PT Lowered to $96 at Evercore ISI
April 30, 2024 12:05 PM EDTEvercore ISI analyst Vijay Kumar lowered the price target on GE HealthCare (NASDAQ: GEHC) to $96.00 (from $100.00) while maintaining a Outperform rating.
The analyst comments "GEHC reported org rev declines of -50 bps, with revs of $4.65 Bn coming in ~150M or 3% below ST. The miss was mainly driven by lower capital sales (MRI, CT, ultrasound & monitoring/vents) and was partly offset by better PDx. Geographically, the miss was driven by China as customers paused due to stimulus announcement. 1Q also had some order fulfillment issues in its PCS segment. On the positive side, GMs were up... More
